A synthetic mechano growth factor E Peptide enhances myogenic precursor cell transplantation success.
Myogenic precursor cell (MPC) transplantation is a good strategy to introduce dystrophin expression in muscles of Duchenne muscular dystrophy (DMD) patients. Insulin-like growth factor (IGF-1) promotes MPC activities, such as survival, proliferation, migration and differentiation, which could enhance the success of their transplantation. Alternative splicing of the IGF-1 mRNA produces different muscle isoforms. The mechano growth factor (MGF) is an isoform, especially expressed after a mechanical stress. A 24 amino acids peptide corresponding to the C-terminal part of the MGF E domain (MGF-Ct24E peptide) was synthesized. This peptide had been shown to enhance the proliferation and delay the terminal differentiation of C(2)C(12) myoblasts. The present study showed that the MGF-Ct24E peptide improved human MPC transplantation by modulating their proliferation and differentiation. Indeed, intramuscular or systemic delivery of this synthetic peptide significantly promoted engraftment of human MPCs in mice. In vitro experiments demonstrated that the MGF-Ct24E peptide enhanced MPC proliferation by a different mechanism than the binding to the IGF-1 receptor. Moreover, MGF-Ct24E peptide delayed human MPC differentiation while having no outcome on survival. Those combined effects are probably responsible for the enhanced transplantation success. Thus, the MGF-Ct24E peptide is an interesting agent to increase MPC transplantation success in DMD patients.
Mills
P
P
Unité de recherche en Génétique humaine, Centre Hospitalier de l'Université Laval, Ste-Foy, Québec, Canada.
Dominique
J C
JC
Lafrenière
J F
JF
Bouchentouf
M
M
Tremblay
J P
JP
D000818:Animals; D017690:Cell Transplantation; D002478:Cells, Cultured; D002648:Child; D016189:Dystrophin / Q000235:genetics; D006133:Growth Substances; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000235:genetics* / Q000494:pharmacology; D008297:Male; D051379:Mice; D016513:Mice, SCID / Q000502:physiology; D018482:Muscle, Skeletal / Q000187:drug effects / Q000502:physiology*; D012333:RNA, Messenger / Q000235:genetics; D013234:Stem Cells / Q000187:drug effects / Q000502:physiology*; D014183:Transplantation, Heterologous; D016896:Treatment Outcome
D016189:Dystrophin; D006133:Growth Substances; D012333:RNA, Messenger; C523997:mechano-growth factor E, human; D007334:Insulin-Like Growth Factor I